Michael Freeman
Stock Analyst at Raymond James
(2.02)
# 3,059
Out of 4,981 analysts
6
Total ratings
60%
Success rate
3.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Freeman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Assumes: Outperform | $14 | $6.97 | +100.86% | 1 | Jun 11, 2025 | |
| TECX Tectonic Therapeutic | Reinstates: Outperform | $76 | $16.59 | +358.11% | 1 | Jun 11, 2025 | |
| DYN Dyne Therapeutics | Assumes: Outperform | $37 | $12.85 | +187.94% | 1 | Jun 11, 2025 | |
| IRON Disc Medicine | Reinstates: Strong Buy | $89 | $59.81 | +48.80% | 1 | Jun 11, 2025 | |
| RNA Avidity Biosciences | Initiates: Strong Buy | $65 | $40.22 | +61.61% | 1 | Jun 11, 2025 | |
| BHC Bausch Health Companies | Initiates: Market Perform | $8 | $7.18 | +11.42% | 1 | Jul 10, 2024 |
Wave Life Sciences
Jun 11, 2025
Assumes: Outperform
Price Target: $14
Current: $6.97
Upside: +100.86%
Tectonic Therapeutic
Jun 11, 2025
Reinstates: Outperform
Price Target: $76
Current: $16.59
Upside: +358.11%
Dyne Therapeutics
Jun 11, 2025
Assumes: Outperform
Price Target: $37
Current: $12.85
Upside: +187.94%
Disc Medicine
Jun 11, 2025
Reinstates: Strong Buy
Price Target: $89
Current: $59.81
Upside: +48.80%
Avidity Biosciences
Jun 11, 2025
Initiates: Strong Buy
Price Target: $65
Current: $40.22
Upside: +61.61%
Bausch Health Companies
Jul 10, 2024
Initiates: Market Perform
Price Target: $8
Current: $7.18
Upside: +11.42%